Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Authors
Keywords
-
Journal
Journal of the American Heart Association
Volume 9, Issue 24, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-12-02
DOI
10.1161/jaha.120.018136
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes
- (2020) Allie S. Carew et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Haptoglobin Phenotype Is Associated With High-Density Lipoprotein–Bound Hemoglobin Content and Coronary Endothelial Dysfunction in Patients With Mild Nonobstructive Coronary Artery Disease
- (2019) Rabea Asleh et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population
- (2019) Sanam Ebtehaj et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Impact of ADCY9 Genotype on Response to Anacetrapib
- (2019) Jemma C. Hopewell et al. CIRCULATION
- Role of HDL function and LDL atherogenicity on cardiovascular risk: A comprehensive examination
- (2019) Álvaro Hernáez et al. PLoS One
- ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease
- (2018) Steven E. Nissen et al. JAMA Cardiology
- Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque
- (2018) Steven Shea et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- (2017) A. Michael Lincoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study
- (2016) Chaoqun Liu et al. ATHEROSCLEROSIS
- Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance with Clinical Outcomes
- (2016) Jean-Claude Tardif et al. Circulation-Cardiovascular Genetics
- Modulating cholesterol efflux capacity to improve cardiovascular disease
- (2016) Nicholas Brownell et al. CURRENT OPINION IN LIPIDOLOGY
- Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
- (2016) Julian C. van Capelleveen et al. Journal of Clinical Lipidology
- Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance with Clinical Outcomes
- (2016) Jean-Claude Tardif et al. Circulation-Cardiovascular Genetics
- Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study
- (2016) Wijtske Annema et al. Scientific Reports
- Pharmacogenomic Determinants of the Cardiovascular Effects of DalcetrapibCLINICAL PERSPECTIVE
- (2015) Jean-Claude Tardif et al. Circulation-Cardiovascular Genetics
- The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype
- (2015) Leah E. Cahill et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib
- (2015) Stephen J. Nicholls et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pharmacogenomic Determinants of the Cardiovascular Effects of DalcetrapibCLINICAL PERSPECTIVE
- (2015) Jean-Claude Tardif et al. Circulation-Cardiovascular Genetics
- Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study
- (2015) Danish Saleheen et al. Lancet Diabetes & Endocrinology
- The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial
- (2014) Kausik K. Ray et al. EUROPEAN HEART JOURNAL
- HDL and cardiovascular disease
- (2014) Daniel J Rader et al. LANCET
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
- (2014) Anand Rohatgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Haptoglobin Genotype Is a Consistent Marker of Coronary Heart Disease Risk Among Individuals With Elevated Glycosylated Hemoglobin
- (2013) Leah E. Cahill et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study
- (2012) Christie M. Ballantyne et al. AMERICAN HEART JOURNAL
- Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy
- (2012) Natacha Bellanger et al. ATHEROSCLEROSIS
- Current concept of reverse cholesterol transport and novel strategy for atheroprotection
- (2012) Koh Ono Journal of Cardiology
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol
- (2011) Sandhya Sankaranarayanan et al. JOURNAL OF LIPID RESEARCH
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
- (2011) Amit V. Khera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
- (2010) Laurent Yvan-Charvet et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib
- (2009) Christopher P. Cannon et al. AMERICAN HEART JOURNAL
- Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway
- (2008) Giovanna Catalano et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Beyond High-Density Lipoprotein Cholesterol Levels
- (2008) Emil M. deGoma et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started